Nurse Practitioner in Walker, MI Accepting Medicare
4 Nurse Practitioner nurses found. Showing 1 - 4
 Tami Nysse, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1175 Wilson Ave Nw, Walker, MI 49534 Phone: 616-685-8650 Fax: 616-791-2160 |
Katelyn Schutte, FNP - C Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 1550 3 Mile Rd Nw, Walker, MI 49544 Phone: 616-785-3883 |
Lindsey Elie Heathman, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 1175 Wilson Ave Nw, Walker, MI 49534 Phone: 616-685-8650 Fax: 616-791-2160 |
Leda Theres Evans, DNP Nurse Practitioner - Adult Health Medicare: Accepting Medicare Assignments Practice Location: 1175 Wilson Ave Nw, Walker, MI 49534 Phone: 616-685-8650 Fax: 616-791-2160 |
News Archive
New simulation approach predicts efficacy of HIV-prophylaxis medications
A new mathematical simulation approach predicts the efficacy of pre- and post-exposure prophylaxis (PrEP) medications, which help prevent HIV infection. The framework, presented in PLOS Computational Biology by Sulav Duwal and Max von Kleist of Freie Universität Berlin and colleagues, could help streamline development of new PrEP treatments.
Statins lower risk of sepsis in patients on kidney dialysis
Researchers at Johns Hopkins may have discovered an unintended benefit in the drugs millions of Americans take to lower their cholesterol: The medications, all statins, seem to lower the risk of a potentially lethal blood infection known as sepsis in patients on kidney dialysis.
Nomogram aids management of boys with constitutional delay in growth and puberty
A puberty nomogram is better than the classical criteria for identifying boys with constitutional delay in growth and puberty, report researchers.
Key cellular defect in protein synthesis can lead to cancer susceptibility
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec
Alexion Pharmaceuticals, Inc. announced that it has purchased patents and assets from Germany-based Orphatec Pharmaceuticals GmbH related to an investigational therapy for patients with molybdenum cofactor deficiency (MoCD) Type A, a devastating ultra-rare genetic disorder characterized by severe brain damage and rapid death in newborns.
› Verified 3 days ago
Registered Nurse
Physician Assistant
Nurse Practitioner
Licensed Practical Nurse